This Article Full Text Full Text (PDF) All Versions of this Article: 0008-5472.CAN-08-2611v1 69/6/2487    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Shurin, M. R. Articles by Kagan, V. E. Search for Related Content PubMed PubMed Citation Articles by Shurin, M. R. Articles by Kagan, V. E.

Recognition of Live Phosphatidylserine-Labeled Tumor Cells by Dendritic Cells: A Novel Approach to Immunotherapy of Skin Cancer

Departments of ¹ Pathology and ² Immunology, University of Pittsburgh Medical Center, ³ Department of Environmental and Occupational Health, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, Pennsylvania

Requests for reprints: Valerian E. Kagan, Center for Free Radical and Antioxidant Health, Department of Environmental and Occupational Health, University of Pittsburgh, Pittsburgh, PA. Phone: 412-624-9479; Fax: 412-624-9361; E-mail: kagan{at}pitt.edu or Michael R. Shurin, Clinical Immunopathology, Department of Pathology, University of Pittsburgh, Pittsburgh, PA; Phone: 412-647-6140; Fax: 412-648-8158; E-mail: shurinmr{at}upmc.edu.

Key Words: Phosphatidylserine • Dendritic cells • Melanoma • Lymphoma • Topical therapy • Apoptosis • Necrosis • Endocytosis

Dendritic cells (DC) loaded with tumor antigens from apoptotic/necrotic tumor cells are commonly used as vaccines for cancer therapy. However, the use of dead tumor cells may cause both tolerance and immunity, making the effect of vaccination unpredictable. To deliver live tumor "cargoes" into DC, we developed a new approach based on the "labeling" of tumors with a phospholipid "eat-me" signal, phosphatidylserine. Expression of phosphatidylserine on live tumor cells mediated their recognition and endocytosis by DC resulting in the presentation of tumor antigens to antigen-specific T cells. In mice, topical application of phosphatidylserine-containing ointment over melanoma induced tumor-specific CTL, local and systemic antitumor immunity, and inhibited tumor growth. Thus, labeling of tumors with phosphatidylserine is a promising strategy for cancer immunotherapy. [Cancer Res 2009;69(6):2487–96]

This article has been cited by other articles:

				G. V. Shurin, I. L. Tourkova, R. Kaneno, and M. R. Shurin Chemotherapeutic Agents in Noncytotoxic Concentrations Increase Antigen Presentation by Dendritic Cells via an IL-12-Dependent Mechanism J. Immunol., July 1, 2009; 183(1): 137 - 144. [Abstract] [Full Text] [PDF]